TYRA Stock Analysis: Buy, Sell, or Hold?
TYRA - Tyra Biosciences, Inc. Common Stock
$34.60
-1.69 (-4.66%)
▼
5d:
-5.26%
30d:
+3.87%
90d:
+33.28%
HOLD
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
TYRA is down 5.2% this week, but smart money is accumulating calls. Top strike: $35 2026-05-15 with 23 OI. Call ratio: 81% View Scanner →
Strength: 5.7/10
Get Alerted When TYRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TYRA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TYRA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TYRA is currently trading at $34.60, which is considered fair relative to its 30-day fair value range of $33.24 to $37.14.
Technical Outlook: Technically, TYRA is in a strong uptrend. The price is currently testing key support at $34.67. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $49.51 (+36.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TYRA is in a strong uptrend. The price is currently testing key support at $34.67. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $49.51 (+36.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$33.24 -
$37.14
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 36.4% below Wall St target ($49.51)
- CAUTION: Recommendation downgraded due to -5.3% 5-day decline
Fair Price Analysis
30-Day Fair Range
$33.24 -
$37.14
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$34.67
Resistance Level
$39.15
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.62
Wall Street Target
$49.51
(+36.4%)
Share & Embed Analysis
Last updated: March 30, 2026 4:48 PM ET
Data refreshes hourly during market hours. Next update: 5:48 PM
Data refreshes hourly during market hours. Next update: 5:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TYRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Robert J More
SELL
10000 shares
2025-12-19
Robert J More
SELL
246871 shares
2025-11-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$132 | 48 HOLD |
